Bioxodes plans to raise EUR 70m to bring to market its hemorrhagic stroke drug candidate – CEO

30 Jun 2025 | 15:38 EDT | Belgium | Healthcare-Instruments | Mergermarket | Proprietary

by **Anastasia Gnezditskaia**

- Targets VC investors, partnerships in China
- Mandated KBC Securities for the Series B round
- Expects to bring ischemic stroke compound to market in 2029

Bioxodes plans to raise EUR 70m in a Series B round to finance the completion of clinical trial and bring to market its hemorrhagic stroke drug candidate, CEO Marc Dechamps said.

The Belgian biotechnology company started talks with investors in April, following the receipt of positive interim data from the Phase 2a study, he said. It plans to complete the funding round by late 2026 or 2027, targeting global VCs as investors, he added.

Management has mandated KBC Securities to assist with the funding round, Dechamps said.

It tentatively plans an exit sale to a preferably global pharma player, but is also considering a regional one, particularly in Asia. It also considers an IPO as a possibility, prior to which it might raise a crossover round, with the decision to be made around 2028, without providing further details.

The company has raised EUR 37.2m in total including EUR 15m earlier this year in Series A, enables it to finance the Phase 2a clinical trial. Current backers include three public entities—among them SFPIM—as well as several family offices, the CEO said.

Apart from VC investors, the company is interested in approaches from pharmaceutical companies for partnership, particularly in Japan and China with stroke being a widespread disease in the latter.

The Gosselies-headquartered company has a headcount of 12.

Technology and milestones

Bioxodes is working on bringing to market its main compound BIOX-101, which has a combination of anti-inflammatory and antithrombotic properties. This makes it a promising candidate for a range of

thrombo-inflammatory diseases, starting with hemorrhagic stroke, according to the company's web site.

BIOX-101, which has completed the Phase 2a study for patients with intracerebral hemorrhage (ICH), has been granted an Orphan Drug Designation (ODD) for ICH in the US and in Europe.

The company has received an interim report from the Phase 2a study of BIOX-101 for ICH and plans to finalize it early next year, Dechamps said.

Bioxodes will initiate the placebo-controlled Phase 2b study for ICH focused on efficacy, with around 120 patients to be enrolled, he said, adding that the number of patients is being debated. The Phase 2b will start in early 2027.

The company looks to receive regulatory approval in 2028 and bring the main compound to market by the end of 2029. Given the ODD designation, it is hoping to receive fast-track approval from US FDA and EU's EMA, the CEO said.

The future financing round will also help the company to advance the study of the second indication of the compound, namely for the treatment of ischemic stroke, currently at the discovery stage. It considers bringing to the clinic two more indications, now in the assessment mode, with a focus on preventing thrombo-inflammatory and inflammatory diseases, he said.

by Anastasia Gnezditskaia in Amsterdam

[Editor's note: This article has been amended post-publication to clarify that Bioxodes will start the Phase 2b study for ICH in early 2027.]

Relationships

Targets

Bioxodes

Bioxodes SA

Sellers

SFPIM

Geography	Belgium
Sectors	Healthcare, Healthcare, Healthcare-Instruments

Topics: Advisory Appointment | Companies for sale | Cross Border | Growth Capital Raise | Joint Ventures/Partnerships | Private Equity M&A

Source: Proprietary